Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
Bank of America's $72.5M Epstein Settlement: What You Need to Know 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
Apple Turns 50: From Garage Startup to AI Crossroads 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
VANCOUVER, B.C., Jan. 04, 2017 -- Novelion Therapeutics, Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, announced today that the company will participate in the 35th Annual J.P. Morgan Healthcare Conference in San Francisco. Chief Executive Officer Mary Szela is scheduled to present on Wednesday, January 11, 2017 at 4:00 p.m. PST (7:00 p.m. EST).
The presentation will be webcast live and may be accessed for up to 30 days following the conference by visiting the “Investors” section of Novelion’s website, www.novelion.com.
About Novelion Therapeutics
Novelion Therapeutics is a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases. The company seeks to advance its portfolio of rare disease therapies by investing in science and clinical development. Novelion has a diversified commercial portfolio through its indirect subsidiary, Aegerion Pharmaceuticals, Inc., which includes MYALEPT® and JUXTAPID®, and is also developing zuretinol acetate for the treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes.
CONTACT: Amanda Murphy, Director, Investor Relations & Corporate Communications Novelion Therapeutics 857-242-5024 [email protected]
